Article Text

Download PDFPDF
Rifaximin induces and maintains clinical remission in a dachshund with chronic enteropathy: antibiotic-responsive diarrhoea or inflammatory bowel disease?
  1. Alessandro Menozzi1,
  2. Manuel Dall'Aglio1,
  3. Fausto Quintavalla1,
  4. Valentina Meucci2 and
  5. Simone Bertini1
  1. 1 Department of Veterinary Science, University of Parma, Parma, Italy
  2. 2 Department of Veterinary Science, University of Pisa, Pisa, Italy
  1. Correspondence to Dr Alessandro Menozzi; alessandro.menozzi{at}


A two-year-old male dachshund was presented with a long-term history of chronic small intestine diarrhoea. The dog had been previously treated with several antibiotics, with temporary remission of clinical signs, relapsing each time the therapy was discontinued. On the basis of clinical signs, history and on the investigations performed which failed to detect any other cause of disease, a diagnosis of antibiotic-responsive diarrhoea (ARD) or small intestine bacterial overgrowth secondary to inflammatory bowel disease was made. A three-week antibiotic treatment with rifaximin by oral route was prescribed, achieving a prompt clinical remission but diarrhoea relapsed shortly after the end of drug administration. A continuous therapy with rifaximin was therefore established, allowing to maintain the dog in complete remission, without any side effect. The efficacy shown by rifaximin in this report suggests, for the first time, that this drug could be a good choice for long-term treatment of ARD.

  • Diarrhoea
  • Dogs
  • Gastrointestinal
View Full Text

Statistics from


  • Contributors AM conceived the treatment with rifaximin wrote the manuscript with SB; MD performed the clinical evaluation and the investigations; FQ contributed to the manuscript; VM contributed to the investigations; SB co-wrote the manuscript with AM.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement The datasets used and/or analysed during the currentstudy are available from the corresponding author on reasonable request.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.